What a real hormone workup involves, and what gets sold instead

The ads target a feeling most adults past 40 recognize: tired by mid-afternoon, sleeping worse, thicker around the middle, less interested in sex. One company offers to mail you a saliva kit that will show whether your hormones are in balance. Another will have a clinician prescribe testosterone after a short video visit and a home blood sample.

Both pitches treat a hormone evaluation as one step: test, then treat. In guideline-based medicine it is a sequence. Across the conditions people most often suspect in themselves, from low testosterone to an underactive thyroid to perimenopause, the guidance keeps returning to four rules:

1. Symptoms and physical signs come first. They decide whether a test is worth ordering at all.
2. The test has to be the right one, taken at the right time. Time of day, fasting and the menstrual calendar can change what a number means.
3. An abnormal result is confirmed before anyone applies a label. One value is a starting point, not a verdict.
4. The result is read against a standardized assay and a fitting reference range. A number is only as good as the method behind it.

Those rules explain why no blood or saliva panel can tell you that your hormones are “balanced.” The guidelines below ask narrower questions. Is one specific hormone consistently too high or too low? Was it measured properly? Does it explain the symptoms in front of the clinician? A report that grades your hormones as balanced or unbalanced is answering a question none of them poses.

Rule one: symptoms decide whether a test is worth ordering

The Endocrine Society’s 2018 testosterone guideline, drafted by a ten-member task force using formal evidence grading, sets the bar plainly. It recommends diagnosing low testosterone, which doctors call hypogonadism, only in men who have both symptoms or signs that fit and testosterone levels the guideline calls “unequivocally and consistently low” on blood tests. A low reading without matching symptoms doesn’t meet that definition. Neither do symptoms alone. The society grades this rule a strong recommendation backed by moderate-quality evidence.

The same society’s 2008 guideline on diagnosing Cushing’s syndrome, a condition of too much of the hormone cortisol, is just as specific about who gets tested. The first step is ruling out glucocorticoid medicines, the steroid family that can produce the same picture on their own. Testing is then recommended for people with several features of the syndrome that are progressing, and for people with an adrenal incidentaloma, a lump on an adrenal gland found by chance on a scan done for something else. The society grades both as strong recommendations, though it rates the evidence behind them as low or very low.

Thyroid testing shows where screening ends and evaluation begins. The U.S. Preventive Services Task Force, which reviews preventive care for people without symptoms, issued an I statement in 2015 on screening nonpregnant adults: the evidence was insufficient to weigh benefits against harms. That is not a recommendation against testing, and it says nothing about someone who has symptoms. A 2024 surveillance review found no new evidence that would justify an update. How screening differs from testing someone who already feels unwell is laid out in our explainer on what medical tests can tell you.

Rule two: the right test, taken at the right time

For testosterone, the Endocrine Society names the starting test: total testosterone, drawn in the morning while fasting and measured with an accurate and reliable method. When the result sits near the bottom of the normal range, or when a man has a condition that changes sex hormone-binding globulin (a blood protein that carries testosterone), the guideline adds a measure of free testosterone, done by a technique called equilibrium dialysis or estimated with an accurate formula. An after-lunch afternoon sample isn’t the test the guideline describes.

For Cushing’s syndrome, one of the accepted first tests is late-night salivary cortisol. So saliva testing isn’t worthless in itself. Used this way it measures one hormone, at one time of day, to answer one question, unlike a panel that grades a dozen hormones against one another.

Perimenopause shows why timing matters. The STRAW+10 staging system, published in 2012 by a workshop backed by the National Institutes of Health and several professional societies, treats the menstrual calendar as the main criterion. Blood markers such as follicle-stimulating hormone (FSH) are supportive only, and the authors wrote that they should not be treated as required for diagnosis. In the late transition, which lasts one to three years on average, FSH can read in the menopausal range on one draw and in the range of a woman’s earlier reproductive years on another. The U.S. Food and Drug Administration defines menopause itself by the calendar: 12 months in a row without a period.

Polycystic ovary syndrome was renamed in May 2026. Its new name, polyendocrine metabolic ovarian syndrome (PMOS), came out of a global consensus process involving 56 organizations. A 2026 special report in the American Journal of Obstetrics and Gynecology stresses that the diagnostic criteria did not change. PMOS still requires two of three findings: irregular cycles with ovulation problems, signs of excess androgens (male-pattern hormones) on exam or in blood tests, and either a high anti-Müllerian hormone (AMH) level or many follicles on ultrasound. The report specifies that the third criterion applies to adults.

Rule three: an abnormal result gets confirmed before it gets a label

The Endocrine Society recommends confirming a low testosterone result by repeating the fasting morning measurement. Once a deficiency is confirmed, it recommends telling a testicular cause from a pituitary or brain one, and suggests, as a weaker recommendation, further evaluation to pin down the cause. Low testosterone is a finding with explanations, not just a number to be topped up.

TRAVERSE, a large testosterone safety trial published in The New England Journal of Medicine in 2023, shows the standard in practice. It enrolled 5,246 men aged 45 to 80 who had symptoms of low testosterone and two separate fasting levels below 300 nanograms per deciliter. That 300 figure was the trial’s entry rule, not a universal cutoff.

The Cushing’s guideline builds confirmation into every branch. An abnormal first test leads to an endocrinologist and a second test. Two normal results, the guideline says, mean no further evaluation. Knowing when to stop testing matters as much as knowing when to start.

Thyroid numbers drift too. The Task Force notes that TSH, the main thyroid screening hormone, can swing by as much as half of its average value from one day to the next, and that labs set their reference intervals from the spread of results across the general population. It describes repeat testing over three to six months to confirm or rule out an abnormal finding. About 37% of people with subclinical hypothyroidism, a raised TSH with normal thyroid hormone, return to normal on their own. The Task Force names false positives, labeling, overdiagnosis and overtreatment as the most important harms, particularly when TSH is below 10. Why a single flagged value so often fades on a repeat is the subject of our piece on one flagged lab number.

Rule four: a number means only what its assay and range can support

Two labs can measure the same blood and report different testosterone or estradiol values, because they use different assays, the chemical methods behind a lab result. The Centers for Disease Control and Prevention runs a Hormone Standardization Program, known as HoSt, that certifies testosterone and estradiol assays. To be certified, a testosterone assay’s average bias has to stay within 6.4%. An estradiol assay has to stay within 12.5% at levels above 20 picograms per milliliter.

CDC updates its certified lists quarterly. Taking part is voluntary, so absence from the list doesn’t prove an assay is inaccurate; the list just can’t vouch for it. CDC notes that labs using certified assays can rely on reference ranges and decision points that were built with those same methods.

The range printed beside your result belongs to the lab and its method. A range built for one assay or population doesn’t automatically carry over to another; how ranges get built in the first place is explained elsewhere in this series. Federal lab certification under CLIA is a separate layer. It governs how a laboratory operates, not whether a particular hormone panel answers a clinical question, a distinction our article on direct-to-consumer labs walks through.

Where the hormone marketplace breaks the rules

Saliva panels that promise balance

Noridian Healthcare Solutions, a regional Medicare contractor, publishes a coverage policy on salivary hormone testing, last revised for services from October 16, 2025. It treats evening salivary cortisol for diagnosing Cushing’s syndrome as the only salivary hormone test that is reasonable and necessary. Salivary thyroid, testosterone, estrogen, parathyroid and growth hormone measurements are classed as investigational, with the accuracy of measurement and a lack of standardization given as the reasons.

A commercial insurer, Aetna, reached a similar place in a policy last reviewed in August 2026. It lists commercial saliva female hormone profiles, saliva adrenal stress profiles and urine hormone-metabolite panels as experimental, investigational or unproven, and notes the absence of evidence that such panels change how patients are managed. In the library’s evidence vocabulary, saliva sex-hormone panels sold to measure balance are insufficient: too poorly standardized, and aimed at a target too loosely defined, to test. They break rule two and rule four at once. Kits you collect yourself and order online get fuller treatment in our pieces on home tests and consumer labs.

Compounded “bioidentical” hormones

Compounded hormones are mixed by a pharmacy for an individual prescription. They are not FDA-approved, so they skip the agency’s premarket review of safety, effectiveness and labeling.

In 2020 the National Academies of Sciences, Engineering, and Medicine completed an FDA-sponsored study of compounded bioidentical hormone therapy. It concluded that the evidence for its clinical usefulness is insufficient, and that marketing claims of superior safety and effectiveness aren’t backed by well-designed studies. It warned that the lack of standardization raises the chance of overdosing, underdosing or contamination. Noting that millions of people use these products, it recommended restricting them to two situations: a documented allergy to an ingredient in an FDA-approved product, or a documented need for a dosage form no approved product offers. It also urged a review of ten hormones, including estradiol, testosterone and progesterone, plus pellet implants, as candidates for FDA’s list of drugs considered too difficult to compound.

A 2023 document from the American College of Obstetricians and Gynecologists, Clinical Consensus No. 6, pushes the point further. It describes bioidentical as a marketing term used to imply that compounded products are natural and therefore safer, and points out that FDA-approved menopause medicines themselves use bioidentical hormones, synthetic ones, or both. Its conclusion: compounded bioidentical menopausal hormone therapy “should not be prescribed routinely when FDA-approved formulations exist.” ACOG says long-term randomized trials comparing the two are still needed. So the claim that compounded hormones are safer is insufficient in the library’s terms: untested, not disproven. FDA’s Office of Women’s Health says it has no evidence that compounded bioidentical hormones are safe and effective, or safer than approved therapy.

Approved products’ risk picture just changed. In November 2025 the Department of Health and Human Services announced that FDA was asking manufacturers to remove boxed-warning statements about heart disease, breast cancer and probable dementia from menopausal hormone therapy labels, and on February 12, 2026, FDA approved the first six revised labels. The boxed warning for endometrial cancer stays on systemic estrogen-alone products. A compounded product has no FDA-approved label to revise. If you use an estrogen product and aren’t sure what else is in your prescription or why, the endometrial-cancer warning is a good reason to put that question to the prescriber and the pharmacist.

Telehealth testosterone

Federal law lists testosterone as a Schedule III controlled substance, under anabolic steroids. Prescribing a controlled substance by video to someone a clinician has never examined in person is possible right now because of a temporary rule. The Drug Enforcement Administration and HHS have now renewed the COVID-19 telemedicine exceptions four times; the current renewal runs from January 1 through December 31, 2026. A permanent special-registration system that DEA proposed in January 2025 drew more than 6,475 comments. As of October 28, 2026, the Federal Register showed no final version of it and no further extension beyond December 31, 2026.

The label has shifted too. In February 2025, after TRAVERSE, FDA told the makers of all testosterone products to remove boxed-warning language about increased cardiovascular risk, to add a blood-pressure warning where one was missing, and to keep a Limitation of Use statement on age-related low testosterone. The agency describes testosterone as approved only for men with low levels together with an associated medical condition.

TRAVERSE itself showed both sides. Among men with existing heart disease or high cardiovascular risk, major heart events occurred in 7.0% of the testosterone group and 7.3% of the placebo group, over a mean treatment period of about 22 months. Atrial fibrillation, acute kidney injury and pulmonary embolism, a blood clot in the lungs, were more common with testosterone. The trial was funded by AbbVie and others.

The Endocrine Society recommends against starting testosterone in men planning to father a child soon, a strong recommendation resting on low-quality evidence. It says the same for men with breast or prostate cancer, a raised PSA without a urology evaluation, a high hematocrit (the share of blood made up of red cells), untreated severe sleep apnea, a heart attack or stroke in the past six months, or a clotting disorder, among other conditions. An examination and baseline tests exist to catch those. When testing and prescribing happen in one transaction, rules three and four are the ones most at risk.

Questions to ask a clinic or test seller before you pay

Each maps to one of the four rules; a legitimate service will have specific answers.

1. Which of my symptoms or findings justify this test? If the answer is that everyone over 40 should be checked, you’re hearing a screening pitch, not an evaluation.
2. When will the sample be taken, and why then? Ask about time of day, fasting and, if you still have periods, where in the cycle.
3. If a result comes back abnormal, will you repeat it before prescribing anything? Confirmation is built into the testosterone and Cushing’s guidelines, and the Task Force describes repeat thyroid testing too.
4. Which assay will be used, and whose reference range? For testosterone and estradiol, you can ask whether the method is on CDC’s certified list.
5. Who interprets the result, and will they look for a cause? A finding of low testosterone, for instance, comes with a search for why.
6. What happens if my results are normal? A good answer points toward other explanations for your symptoms. A weak one points toward a product anyway.
7. Is the treatment you’d prescribe FDA-approved? If it’s compounded, ask what documented reason rules out an approved product.
8. For telehealth prescriptions, what happens after December 31, 2026? Ask who will examine you in person, who monitors blood counts and blood pressure, and what happens if the federal flexibility lapses.

When to book a proper evaluation, and with whom

These situations call for a primary care visit; that clinician can decide whether an endocrinologist (a hormone specialist), urologist or gynecologist should be involved:

• Symptoms of low testosterone and one low result, especially from an afternoon or non-fasting sample. Confirmation and a search for a cause are the steps the guideline describes next.
• Several physical changes that keep progressing over months, or an adrenal lump found by chance on a scan. Both fall inside the Cushing’s guideline’s testing criteria, with specialist referral after an abnormal screen.
• An abnormal TSH on a routine panel. The Task Force’s description of repeat testing over months applies before anyone settles on a label.
• Irregular cycles together with acne or unwanted hair growth. PMOS assessment uses defined criteria; our article on reproductive symptoms covers when those warrant a visit.
• Uncertainty about what’s in a compounded hormone prescription. Bring the label and put the question to both the prescriber and the pharmacist.

If you already use testosterone and develop sudden chest pain or sudden shortness of breath, call 911. TRAVERSE recorded more pulmonary embolisms with testosterone than with placebo. Our guide to symptoms that warrant 911 covers the rest of that list. For the mechanics of getting to a specialist, see the companion piece on how referrals move.

The question that separates an evaluation from a sale

The most revealing of those questions is number six: what happens if the result is normal?

A guideline-based workup has a real answer: a normal, properly timed result rules something out, and the clinician moves on to the other common causes of fatigue, poor sleep, low mood and low libido. A service built around selling one treatment may struggle to answer, and that struggle tells you what you need to know before you pay.

Sources

1. The Journal of Clinical Endocrinology & Metabolism (Endocrine Society). “Bhasin S et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab, 2018. PubMed. DOI: 10.1210/jc.2018-00229.” pubmed.ncbi.nlm.nih.gov
2. The Journal of Clinical Endocrinology & Metabolism (Endocrine Society). “Nieman LK et al. "The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab, 2008. PubMed. DOI: 10.1210/jc.2008-0125.” pubmed.ncbi.nlm.nih.gov
3. The New England Journal of Medicine. “Lincoff AM et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." N Engl J Med, 2023. PubMed. DOI: 10.1056/NEJMoa2215025.” pubmed.ncbi.nlm.nih.gov
4. Menopause (The North American Menopause Society). “Harlow SD et al. "Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging." Menopause, 2012. PubMed. DOI: 10.1097/gme.0b013e31824d8f40.” pubmed.ncbi.nlm.nih.gov
5. American Journal of Obstetrics and Gynecology. “Bahri-Khomami M et al. "From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: what obstetricians and gynecologists need to know." Am J Obstet Gynecol, 2026. PubMed. DOI: 10.1016/j.ajog.2026.08.024.” pubmed.ncbi.nlm.nih.gov
6. The Lancet. “Teede HJ et al. "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." Lancet, 2026. PubMed. DOI: 10.1016/S0140-6736(26)00717-8.” pubmed.ncbi.nlm.nih.gov
7. Obstetrics & Gynecology (American College of Obstetricians and Gynecologists). “American College of Obstetricians and Gynecologists. "Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6." Obstet Gynecol, 2023. PubMed. DOI: 10.1097/AOG.0000000000005395.” pubmed.ncbi.nlm.nih.gov
8. U.S. Preventive Services Task Force. “Thyroid Dysfunction: Screening (final recommendation, March 24, 2015).” uspreventiveservicestaskforce.org
9. Centers for Disease Control and Prevention. “HoSt FAQs (Clinical Standardization Programs, Hormone Standardization).” cdc.gov
10. Noridian Healthcare Solutions (Medicare Administrative Contractor), via CMS Medicare Coverage Database. “Local Coverage Determination L36846: Measurement of Salivary Hormones.” cms.gov
11. Aetna. “Clinical Policy Bulletin 0499: Nonstandard Laboratory Test Panels.” aetna.com
12. National Academies of Sciences, Engineering, and Medicine. “Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones Except for Specific Medical Circumstances (news release, July 1, 2020).” nationalacademies.org
13. U.S. Food and Drug Administration, Office of Women's Health. “Menopause & Hormones: Common Questions (2019).” fda.gov
14. U.S. Department of Health and Human Services. “FACT SHEET: FDA Initiates Removal of "Black Box" Warnings from Menopausal Hormone Replacement Therapy Products (November 10, 2025).” hhs.gov
15. U.S. Food and Drug Administration. “FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (February 12, 2026).” fda.gov
16. U.S. Food and Drug Administration. “FDA issues class-wide labeling changes for testosterone products (February 28, 2025).” fda.gov
17. Legal Information Institute, Cornell Law School. “21 CFR § 1308.13 – Schedule III.” law.cornell.edu
18. Drug Enforcement Administration and Department of Health and Human Services (Federal Register). “Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (90 FR 61301, December 31, 2025).” federalregister.gov
19. Drug Enforcement Administration (Federal Register). “Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed rule, 2025-01099, 90 FR 6541, January 17, 2025).” federalregister.gov
20. U.S. Department of Health and Human Services (telehealth.hhs.gov). “Prescribing controlled substances via telehealth.” telehealth.hhs.gov